Link Technologies, the oligonucleotide reagent manufacturer, is offering TC RNA monomers under an exclusive licence-agreement with Agilent Technologies.
Under the terms of the agreement, Link will manufacture and sell the four RNA monomer phosphoramidite reagents for use in research.
The reagents will make their debut at TIDEs (Las Vegas) on 18 May, where Dr Douglas Dellinger, principal investigator at Agilent Technologies, will run a workshop entitled 'The Development of a Cost-Effective Large Scale Synthesis Process for RNA Therapeutics'.
These monomers offer advantages over existing RNA chemistry including: lower cost amidites; reduced synthesis cycle times; high-percentage full-length product; and a simple one-step base cleavage and de-protection procedure, affording fast and economical post-synthesis handling.
